Difference in fibrinolytic capacity in young patients with venous thrombosis or ischaemic stroke

Blood Coagulation and Fibrinolysis

Volumn 25, Issue 1, 2014, Pages 61-66

  Skov, Jane ^a   Sidelmann, Johannes J ^a   Bladbjerg, Else Marie ^a   Jespersen, Jørgen ^a,b   Gram, Jørgen ^a,b  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b Hospital of South West Denmark ^*  (Denmark)

Author keywords

fibrinolysis; PAI 1; stroke; thrombophilia test; venous thromboembolism

Indexed keywords

BIOLOGICAL MARKER; FIBRINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN ISCHEMIA; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; FEMALE; FIBRIN CLOT; FIBRINOLYSIS; GENETIC POLYMORPHISM; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; OBESITY; PREVALENCE; PRIORITY JOURNAL; THROMBOPHILIA; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

ADULT; FEMALE; FIBRINOLYSIS; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; STROKE; VENOUS THROMBOSIS;

EID: 84893656695     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0b013e328364c473     Document Type: Article

References (33)

1. Vartiainen E, Puska P, Pekkanen J, Tuomilehto J, Jousilahti P. Changes in risk factors explain changes in mortality from ischaemic heart disease in Finland. BMJ 1994; 309:23-27.
2. Rosendaal FR, Reitsma PH. Genetics of venous thrombosis. J Thromb Haemost 2009; 7 (SUPPL.1):301-304.
3. Lijfering WM, Rosendaal FR, Cannegieter SC. Risk factors for venous thrombosis: current understanding from an epidemiological point of view. Br J Haematol 2010; 149:824-833.
4. Lowe GD. Arterial disease and venous thrombosis: are they related, and if so, what should we do about it? J Thromb Haemost 2006; 4:1882-1885.
5. Lijfering WM, Flinterman LE, Vandenbroucke JP, Rosendaal FR, Cannegieter SC. Relationship between venous and arterial thrombosis: a review of the literature from a causal perspective. Semin Thromb Hemost 2011; 37:885-896.
6. Di Minno MN, Tufano A, Ageno W, Prandoni P, DiMinno G. Identifying highrisk individuals for cardiovascular disease: similarities between venous and arterial thrombosis in perspective. A 2011 update. Intern Emerg Med 2012; 7:9-13.
7. Franchini M, Mannucci PM. Association between venous and arterial thrombosis: clinical implications. Eur J Intern Med 2012; 23:333- 337.
8. Prandoni P, Bilora F, Marchiori A, Bernardi E, Petrobelli F, Lensing AW, et al. An association between atherosclerosis and venous thrombosis. N Engl J Med 2003; 348:1435-1441.
9. Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen PW. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation 2008; 117:93-102.
10. Braekkan SK, Hald EM, Mathiesen EB, Njolstad I, Wilsgaard T, Rosendaal FR, Hansen JB. Competing risk of atherosclerotic risk factors for arterial and venous thrombosis in a general population: the Tromso study. Arterioscler Thromb Vasc Biol 2012; 32:487-491.
11. Pirmohamed M. Warfarin: almost 60 years old and still causing problems. Br J Clin Pharmacol 2006; 62:509-511.
12. Van Es J, Eerenberg ES, Kamphuisen PW, Buller HR. How to prevent, treat, and overcome current clinical challenges of VTE. J Thromb Haemost 2011; (SUPPL.1):265-274.
13. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359:2195-2207.
14. Glynn RJ, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009; 360:1851-1861.
15. Becattini C, Agnelli G, Schenone A, Eichinger S, Bucherini E, Bianchi M, et al. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med 2012; 366:1959-1967.
16. Folsom AR, Aleksic N, Park E, Salomaa V, Juneja H, Wu KK. Prospective study of fibrinolytic factors and incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol 2001; 21:611-617.
17. Gram J, Bladbjerg EM, Moller L, Sjol E, Jespersen J. Tissue-type plasminogen activator and C-reactive protein in acute coronary heart disease. A nested case-control study. J Int Med 2000; 247:205-212.
18. Allman-Farinelli MA. Obesity and venous thrombosis: a review. Semin Thromb Hemost 2011; 37:903-907.
19. Iwaki T, Urano T, Umemura K. PAI-1, progress in understanding the clinical problem and its aetiology. Br J Haematol 2012; 157:291-298.
20. Guimaraes AH, de Bruijne EL, Lisman T, Dippel DW, Deckers JW, Poldermans D, et al. Hypofibrinolysis is a risk factor for arterial thrombosis at young age. Br J Haematol 2009; 145:115-120.
21. GramJ, Sidelmann J, Jespersen J. Does low protein concentration of tissuetype plasminogen activator predict a low risk of spontaneous deep vein thrombosis? Thromb Haemost 1995; 74:718-721.
22. Meltzer ME, Lisman T, de Groot PG, Meijers JC, le Cessie S, Doggen CJ, Rosendaal FR. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. Blood 2010; 116:113-121.
23. Jespersen J, Astrup T. A study of the fibrin plate assay of fibrinolytic agents. Optimal conditions, reproducibility and precision. Haemostasis 1983; 13:301-315.
24. Jespersen J, Sidelmann JJ. A study of the conditions and accuracy of the thrombin time assay of plasma fibrinogen. Acta Haematol 1982; 67:2-7.
25. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven R, de Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369:64-67.
26. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88:3698-3703.
27. Bladbjerg EM, Gram J, Jespersen J, de Maat MP. Internal quality control of PCR-based genotyping methods in research studies and patient diagnostics. Thromb Haemost 2002; 87:812-816.
28. Jespersen J. The diurnal increase in euglobulin fibrinolytic activity in women using oral contraceptives and in normal women, and the generation of intrinsic fibrinolytic activity. Thromb Haemost 1986; 56:183-188.
29. Longstaff C, Thelwell C, Williams SC, Silva MM, Szabo L, Kolev K. The interplay between tissue plasminogen activator domains and fibrin structures in the regulation of fibrinolysis: kinetic and microscopic studies. Blood 2011; 117:661-668.
30. Undas A, Zawilska K, Ciesla-Dul M, Lehmann-Kopydlowska A, Skubiszak A, Ciepluch K, Tracz W. Altered fibrin clot structure/function in patients with idiopathic venous thromboembolism and in their relatives. Blood 2009; 114:4272-4278.
31. Collet JP, Allali Y, Lesty C, Tanguy ML, Silvain J, Ankri A, et al. Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis. Arterioscler Thromb Vasc Biol 2006; 26:2567-2573.
32. Colucci M, Binetti BM, Tripodi A, Chantarangkul V, Semeraro N. Hyperprothrombinemia associated with prothrombin G20210A mutation inhibits plasma fibrinolysis through a TAFI-mediated mechanism. Blood 2004; 103:2157-2161.
33. Poller L, Keown M, Ibrahim S, Lowe G, Moia M, Turpie AG, et al. An international multicenter randomized study of computer-assisted oral anticoagulant dosage vs. medical staff dosage. J Thromb Haemost 2008; 6:935-943.